A phase II study of apatinib combined with S-1 in previously treated refractory metastatic colorectal cancer.

Ning Li,Wenying Deng,Guifang Zhang,Yanwei Guo,Yijie Ma,Qiong Wu,Xinyi Yang,Suxia Luo

A phase II study of apatinib combined with S-1 in previously treated refractory metastatic colorectal cancer.

2019

Ning Li
Wenying Deng
Guifang Zhang
Yanwei Guo
Yijie Ma
Qiong Wu
Xinyi Yang
Suxia Luo

e15016Background: Although regorafenib and fruquintinib have been recommended as the third-line treatment for patients with refractory metastatic colorectal cancer (mCRC), the median survival time ...

Keywords:

Refractory
Colorectal cancer
Phases of clinical research
Pathology
Oncology
Apatinib
Internal medicine
Medicine
previously treated
median survival
Regorafenib
Fruquintinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations